Library

Place of publication:
therapy No. 6 (40) 2020

Summary:
the purpose of the study is to evaluate the effectiveness, safety and the possibility of correcting the neuropsychiatric manifestations of chronic brain ischemia (chemical) drugs Mexidol ^® and Mexidol ^® Forte 250 within the framework of consecutive therapy against the background of arterial hypertension, atherosclerosis (IBS), osteoarthritis or OA) or OA) or OA) rheumatoid arthritis (RA). Material and methods. 134 patients 45–75 years old with a neuroimulated chemical chemicized, combined with hypertension, coronary heart disease and articular pathology were examined. Group 1 (observations) included 79 patients - 30 patients with RA (subgroup 1A) and 49 with the ot of the knee joints (subgroup 1b), who received in the complex therapy Mexidol ^® and Mexidol ^® Fort 250. Group 2 (control) amounted to 55 patients - 25 patients with RA (subgroup 2A) and 30 - with OA (subgroup 2B), which used to use basic therapy without the addition of Mexidol. The dynamics of subjective and physical symptoms were evaluated, values ​​on the scales of CGI, Mosa, MFI 20, anxiety and depression of Hamilton, Tinnetti. Mexidol ^® was prescribed intravenously (500 mg per day) for 14 days with the subsequent oral administration of the drug Mexidol ^® Fort 250 at 250 mg 3 times/day another 60 days. Results. ^® and Mexidol ^® to the standard treatment of drugs in the framework of consistent therapy contributed to an increasing improvement in all studied indicators. In the control groups, the cognitive status did not change. The use of initiating intravenous therapy with Mexidol increased the adherence of patients to the prolonged use of the drug. Conclusion. Violations of the locomotor function in polymorbid patients are partially associated with chemicals. The additional purpose of the consistent infusion and tablet forms of Mexidol significantly improves cognitive functions with the correction of the stability of walking, asthenic manifestations, and increases the motivation for active life. Key words: chronic brain ischemia, Mexidol ^® , Mexidol ^® Fort 250, osteoarthritis, rheumatoid arthritis, arterial hypertension, coronary heart disease.

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova 2020, T. 120, No. 3, P. 87-91

Summary:
an analysis of the clinical efficiency and safety of the use of ethylmethylhydroxypyridine of succinate (Mexidol) in a complex of rehabilitation measures in patients who have undergone ischemic stroke (AI). It is shown that with the terminal use of the drug in patients, restoration of neurological functions is improved, regression of neurological deficiency and cognitive disorders, including improving memory, reducing the manifestation of asthenic syndrome, increasing the level of socio-household adaptation, and improving the psychoemotional state of patients, a decrease in spasticity, increasing spasticity, and increasing the motor and speech activity, praxis, reliable elimination of ignoring syndrome. In patients who have suffered AI, there was a decrease in the blood level of total cholesterol and low-density С-lipoproteins, a decrease in the severity of hypercoagulation. The results of the studies convincingly showed the feasibility of using ethylmethylhydroxypyridine of succinate (Mexidol) at all stages of restoration treatment of patients who suffered AI. Keywords : ethylmethylhydroxypyrididine succinate, Mexidol, rehabilitation, recovery, stroke.

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2020, T. 120, No. 3 issue. 2

Summary:
Purpose of the study. Assessment of the effectiveness and safety of prolonged sequential therapy with Mexidol and Mexidol Forte 250 for a functional outcome in patients with ischemic stroke (AI) in the basin of the internal carotid artery. Material and methods. The study includes 50 patients with the first AI in the carotid pool, which were hospitalized in the SOKB on the 1st day from the onset of the disease. Patients of the main group (n = 25) received Mexidol 500 mg intravenously dropped 1 time per day for 14 days, then Mexidol Forte 250 in tablets of 250 mg 3 times a day for 60 days. Patients of the comparison group (n = 25) received standard basic therapy. The reliability of intergroup differences was evaluated using the Mann-Uiite criterion, the exact criterion of Fisher, and the calculation of relative risk (OR). Statistically significant were the differences at the level of p <0.05. Results. After 14 days of therapy, both groups of patients demonstrated positive dynamics regarding the initial indicators. At the same time, patients who received Mexidol had a higher score on the MOS scale (U = 173.5, P = 0.006) showed a lower score when performing tasks for dynamic praxis (U = 214.0, P = 0.028) and optical Spatial disorders (U = 170.5, p = 0.003), the better strength of memorization (181.5, p = 0.006), and also better performed tasks for generalization (U = 200.5, p = 0.014). By the 74th day, the absence of moderate cognitive disorders (MOS> 26 points) was diagnosed in 17 (68%) patients of the main group and 14 (56%) patients of the comparison group. Differences without a statistically significant difference. At the same time, patients of the main group had a statistically lower score on the NIHSS scale (U = 124.0, p <0.001) and a lower degree of disability: the total score on the MRS 0-2 scale was reached in 19 (76%) patients of the main group and only In 12 (48%) patients of the comparison group (OR = 3.34, F = 0.07, P <0.05). Also, patients who received prolonged sequential therapy with Mexidol and Mexidol Forte 250 had more mild spatial disorders than patients of the comparison group. Conclusion. Conducting consistent therapy with Mexidol and Mexol Forte 250 in the acute and early recovery periods of AI positively affects the regression of focal neurological symptoms, increases the likelihood of independence in everyday life by 3.34 times, and helps to reduce the severity of optical, neurodynamic disorders and memory impairment. Key words: ischemic stroke, Mexidol, Mexidol Fort 250, cognitive impairment, functional outcome.

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova 2020, T. 120, No. 3, Issue. 2, S. 60-65

Summary:
Purpose of the study. Studying the effectiveness and safety of therapy with Mexidol, used intravenously (500 mg 1 time per day) for 14 days, with the subsequent administration of orally, Mexidol Forte 250 in a dose of 250 mg (1 tablet) 3 times a day for 60 days in patients with patients with Chronic ischemia of the brain (Khim) against the background of arterial hypertension and atherosclerosis of brachiocephalous arteries. Material and methods. The observation program includes 52 patients with an established diagnosis of chemicals confirmed by neuroizializational research methods. The main group included 26 patients who, in addition to basic therapy, Mexidol and Mexidol Forte 250. The comparison group consisted of 26 patients who received only basic therapy. Results and conclusion. The high efficiency and safety of consistent therapy (parenteral administration and then taking the tablet form of the drug Mexidol Forte 250) are shown. Against the background of treatment, an improvement in emotional and cognitive statuses, a decrease in static-locomotor disorders, as well as the severity of subjective neurological symptoms is noted. The high commitment of patients on the therapy is shown. Keywords: chronic brain ischemia, arterial hypertension, atherosclerosis of brachiocephalous arteries, Mexidol, Static-Locomotor disorders, cognitive disorders.

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2019, T. 119, No. 12, Issue. 2

Summary:
Purpose of the study. The study of the effectiveness and safety of therapy with Mexidol, prescribed intravenously (500 mg 1 time per day) for 14 days, followed by the oral administration of Mexidol Forte 250 in 250 mg 3 times a day in patients with chronic brain ischemia (chemical). Material and methods. The study includes 56 patients with chemicals, which developed against the background of a combination of arterial hypertension and atherosclerosis. They evaluated the results of physical examination methods (level of blood pressure, heart rate, etc.), complaint dynamics, indicators on the scales of the general clinical impression (CGI), Mosa, asthenia MFI 20, anxiety and depression of Hamilton, Tinnetti. Results and conclusion. The results of the study showed the effectiveness and safety of intravenous administration of Mexidol, followed by the oral administration of Mexidol Forte 250. The specified scheme of therapy contributed to the regression of objective and subjective symptoms of HIM, and led to improvement in the emotional, cognitive and motor spheres. Key words: chronic brain ischemia, atherosclerosis, arterial hypertension, motor disorders, cognitive disorders, Mexidol, Mexidol Fort 250.

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2019, T. 119, No. 9

Summary:
Purpose of the study. Studying the effectiveness and safety of therapy with a medicine (LP) Mexidol, used intravenously (500 mg 1 time per day) in the form of infusions for 14 days, followed by orally orally Mexidol Fort 250 in a dose of 250 mg (1 tablet) 3 times a The day for 60 days in patients with chronic ischemia of the brain against the background of arterial hypertension and atherosclerosis. Material and methods. The open observation program includes 60 patients with an established diagnosis of chronic brain ischemia, confirmed by neuroimaging research methods. Results and conclusion. The results of the study showed high efficiency and safety of sequential therapy (injections and then taking the tablet form of the LP Mexol Forte 250). Against the background of treatment, an improvement in emotional and cognitive status, a decrease in motor disorders, as well as the severity of subjective manifestations are noted. High commitment to patients to the therapy is shown. Keywords: chronic brain ischemia, arterial hypertension, atherosclerosis, ethylmethylhydroxypyrididine succinate, mexidol, cognitive disorders.

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2019, T. 119, No. 8

Summary:
one of the leading causes of mortality, disability and pronounced maladaptation of patients is an ischemic stroke, which accounts for about 80% of all types of acute cerebrovascular accident. At the same time, approximately 2/3 of patients detect residual phenomena of cerebrovascular circulation disorders of varying degrees of severity. Currently, the problem of ischemic stroke is given great attention, and one of the aspects of work in this area is the developed international and domestic recommendations for the prevention of stroke, treatment and rehabilitation of patients who have undergone stroke. The article provides an overview of the latest clinical recommendations for the early management of patients with acute ischemic stroke of the American Association on the Problems of the Heart and the American Association for the Treatment of Stroke, as well as the features of the therapy and prevention of stroke in Russia, European and the USA. Key words: ischemic stroke, clinical recommendations, therapy of ischemic stroke.

Place of publication:
Bulletin of Otorinolaryngology, 2019, T. 84, No. 6

Summary:
with vascular etiology of neurosenate hearing loss, hearing changes can occur as a result of the vertebral-baslar failure of various etiologies. Features of the etiology and pathogenesis of chronic neurosenate hearing loss allow us to consider very promising the use of neuroprotective drugs in the therapeutic complex that can activate the structure and function of neuronal structures of the analyzer trace. Ethylmethylhydroxypirinidine of succinate, possessing comprehensive pharmacological capabilities and a wide spectrum of effects realized at neuronal and vascular levels can be used in the therapy of hearing impairment and intelligibility of speech. Keywords: hearing loss, neurosenate hearing loss, rehabilitation of the auditory function, ethylmethylhydroxypyridine succinate.

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova Stroke No. 4/2019

Summary:
the review presents data on the combined use of Mexidol in combination with drugs of various pharmacotherapeutic groups. Possessing the multimodal action mechanism and a wide range of pharmacological effects, Mexoling enhances the main effect of drugs both in the experiment and in the clinic, increases the effectiveness of therapy prescribed by patients in accordance with current federal standards, and also helps to reduce the severity of complications of diseases. The data on the efficiency and pathogenetic validity of the course combination therapy with other preparations presented in the review indicate the advisability of this approach for the treatment of cerebrovascular and cardiovascular diseases, diseases of the nervous system, open-angle glaucoma, alcohol intoxication and a number of other diseases. Key words: Mexidol, combined therapy, free radicals, lipid oxidation, ischemic stroke, myocardial infarction, coronary heart disease, epilepsy, glaucoma, alcohol intoxication.

Place of publication:
special release of the journal of neurology and psychiatry named after S.S. Korsakov Stroke No. 3.2/2019

Summary:
Purpose of the study. To study in dynamics the rheological properties of blood in patients with acute ischemic stroke (AI) when Mexidol is included in complex therapy. Material and methods. 60 patients with acute AI examined. Mexidol (500 mg/day intravenously within 20 days) received 32 patients, 28 patients received magnesium sulfate (2000 mg/day intravenously for 20 days). The control group included 20 patients without a history of cardiovascular pathology. Assessment of rheological indicators of blood (whole blood viscosity, plasma viscosity, hematocrit, aggregation and deformability of red blood cells, the level of fibrinogen in plasma) was carried out in patients three times: during the first 12 hours, on the 3-5th day and on the 18-20th day and on the 18th-20th day After hospitalization. Results. All patients with a stroke observed a high viscosity syndrome. A statistically significant decrease in blood viscosity was detected in patients receiving Mexidol, by the 3-5th day of the disease at low shift speeds and by the 18-20 days at the speed of the shift from 3-100 S1. By the 18-20th day of the disease, reliable differences in the value of hematocrit (p = 0.026) and the content of fibrinogen (p = 0.017) were revealed in groups of patients receiving various therapy. A reliable increase in the erythrocyte deformability index in patients who received the therapy with Mexidol by the 3-5th day at the shift speeds of 90 and 890 S-1, by the 18-20th day at the shift speeds 90–360 S-1, was recorded. Conclusion. The study shows the effect of Mexol's drug on blood fluidity in the dynamics of acute cerebral ischemia and its effectiveness is proved in reducing blood viscosity by reducing the level of hematocrit and fibrinogen, as well as an improvement in the deformation ability of red blood cells. Keywords: acute ischemic stroke, rheological indicators of blood, blood viscosity, erythrocyte deformability, Mexidol (2-ethyl-6-methyl-3-hydroxypirinate), treatment of brain ischemia.

Place of publication:
New therapeutic journal "Non Nocera" No. 11, 2018

Summary:
cognitive violations of varying degrees are laid by severe economic and emotional burden on the families of patients and society as a whole. Modern methods of therapy in most cases reduce the severity of violations and increase the duration of an active independent life.

Place of publication:
“Neurology, neuropsychiatry, psychosomatics”, 2018; 10 (3): 86–90

Resume:
The purpose of the study is to assess the influence of intravenous administration of Mexidol during the “therapeutic window” on the effectiveness of intravenous thrombolytic therapy (TLT). Patients and methods. A retrospective study includes 123 patients with an ischemic stroke (AI) who conducted intravenous TLT in the conditions of the vascular centers of the Republic of Tatarstan. To assess the dynamics of neurological status, they used the scale of the severity of the National Institute of Health (National Stroke Scale (Nihss). Depending on the initial severity of the neurological deficiency, all patients were divided into three subgroups: with mild severity (Lee) and an assessment by NIHSS at admission <8 points; with moderate severity (si) - with an assessment> 8 and <16 points; With heavy AI (TI) - with an assessment> 16 points. X -ray computed tomography was performed by all patients at the time of admission, 24 hours after the TLT, as well as with a deterioration in the condition. Results. The use of Mexidol at the prehospital stage, followed by TLT in patients with AI positively affects the regression of neurological deficiency, regardless of the severity of the disease. Reliable differences in the degree of regression of the neurological deficiency according to NIHSS 24 hours and 10 days after receipt of patients with TI who were introduced by Mexidol at the prehospital stage were revealed and who did not receive this drug before the implementation of TLT. The use of Mexidol before TLT promotes greater regression of neurological deficiency. A lower frequency of development of hemorrhagic transformations has been established in patients who received Mexidol at the prehospital stage, in comparison with patients who did not use this drug. Conclusion. The data obtained demonstrate the positive effect of Mexidol on the effectiveness and safety of TLT in patients with AI. Keywords: ethylmethylhydroxypyridine succinate; intravenous thrombolytic therapy; ischemic stroke; Neuroprotective therapy.

Place of publication:
neurology, neuropsychiatry, psychosomatics. 2018, No. 10

Summary:
The purpose of the study is to assess the effectiveness of the inclusion of Mexidol in complex drug therapy in patients in the acute period of ischemic (AI) and hemorrhagic stroke. Patients and methods. 60 patients aged 60–74 years with a first -aimed stroke were examined: 34 of them were diagnosed with AI, in 26 - intra -core hemorrhage (Navy). The main group was 31 patients who received, in addition to therapy in accordance with the standards adopted in the Russian Federation, Mexidol. The comparison group included 29 patients who were prescribed only standard therapy. Before and against the background of intravenous drip administration of Mexidol, 500 mg for 10 days, indicators were assessed by the stroke scale of the American National Institute of Health (National Institutes of Health Stroke Scale, NiHSS), the Rivermide mobility index and the Rankin scale and the Bartel index. The percentage absorption of lipid phospholipid complexes in the infrared spectrum of blood serum was also investigated. The control group amounted to 20 practically healthy persons. Results and discussion. It was found that the dynamics of lipid phospholipid complexes of the blood serum correlate with the type of stroke. The inclusion of Mexidol in complex drug therapy in elderly patients in the acute period of AI and Navy contributed to the regression of focal neurological deficiency, improving daily activity and functional independence. Mexidol's reception had a positive effect on the level of phospholipids of neuronal membranes. Conclusion. Mexidol’s positive effect on the level of blood serum phospholipids was noted. The conclusion was made about the effectiveness of its inclusion in the complex therapy of the acute period of AI and hemorrhagic stroke, especially in the elderly. Key words: ischemic stroke; intracassium hemorrhage; therapy; Mexidol; phospholipids.

Place of publication:
“Journal of Neurology and Psychiatry”, 10, 2018

Summary:
antihypoxic, antioxidant and nootropic effects of Mexidol contribute to improving the condition of patients with cerebrovascular pathology. The results of clinical studies show that the sequential scheme for the use of the drug (first intravenously or intramuscularly, then orally) is effective in the complex therapy of ischemic diseases of the brain, vascular surgery, therapy and rehabilitation of patients with degenerative-dystrophic changes in the spine, with neurodegenerative pathology, infectious neuropathies, a and Also in therapy of neuropsychological and autonomic disorders.

Place of publication:
a journal of neurology and psychiatry, 9, 2018; Ext. 2

Summary:
Purpose of the study. To study the clinical efficiency, metabolic and membraneproprothetic effects of Mexidol with transient ischemic attacks (TIA) in the vertebral-baslar system (VBS) in elderly patients with chronic brain ischemia (HIGM). Material and methods. 53 patients aged 60 to 74 years with the first episode of TIA in the WBS against the background of HIGM were examined. The main group included 33 patients who received Mexidol in addition to standard therapy (500 mg for 10 days). The comparison group consisted of 20 patients who received only standard therapy. They studied the dynamics of clinical manifestations of TIA, indicators of the state of oxidant and antioxidant systems, as well as the percentage absorption of lipid phospholipid blood serum complexes in the infrared spectrum. The control group amounted to 20 practically healthy patients. Results and conclusion. The use of Mexidol is associated with faster regression of focal neurological deficiency. The drug reliably reduced the intensity of lipid peroxidation and had a positive effect on the level of phospholipids of neuronal membranes. The identified metabolic and membraneproprothetic effects of Mexidol, as well as the positive effect of the drug on the regression of the focal neurological deficiency substantiate its inclusion in the complex therapy of the TIA in the WBS against the background of HIGM, especially in elderly patients. Key words: transient ischemic attack, vertebral-baslar system, chronic brain ischemia, mexidol, lipid oxidation, phospholipids.

Place of publication:
Journal of Neurology and Psychiatry, 8, 2018

Summary:
Purpose of the study. Assess the effect of mono- and combined therapy with Mexidol with young patients with cerebral angiodistonia. Material and methods. 90 patients (38 men and 52 women aged 25 to 44 years) were examined with vegetative dysfunction syndrome in the form of asthenovegetative and cephalgic syndromes taking Mexidol (1st group, 30 patients), Vinpocetin (2nd group, 30) and 30) and 30) and 30) and 30) and 30) Their combination (3rd group, 30). The condition of cerebral hemodynamics was evaluated using an algorithm for complex ultrasound examination, the state of autonomic regulation - by analyzing the variability of the heart rhythm, the functional state of microcirculation - by conducting a laser Doppler flower before and 10 days after the course of use of drugs. Results and conclusion. Mexidol in both mono and complex treatment of patients with cerebral angiodistonia possessed a vegetostabilizing, cerebrooprotective effect. An improvement in cerebral hemodynamics and microhemocirculation was revealed. As part of combined therapy (Mexidol and Vinpocetin), the effect of each drug was enhanced, and the adaptation of cerebral blood flow took place much faster than when using only winepocetine. Thus, the use of combined therapy (Mexidol and Vinpocetin) in patients with cerebrovascular pathology helps to minimize the negative prognosis of the development of the disease and may impede the development of acute cerebrovascular disorders. Keywords: Mexidol, Vinpocetin, microcirculatory disorders, autonomic dystonia, laser Doppler floometry, Cerebral angiodistonia.